Joel Reiss sold $4.2M of TDG
Co-Chief Operating Officer at TransDigm Group INC. 3,000 shares at an average of $1,406.07, traded Aug 20, 2025, filed Aug 20, 2025.
Score components
- +20RoleCOO
- +25Trade size$4.2M at market
- +10Share of holdings soldSold 45% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -2.2%, 3m +2.2%, 6m +0.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001656109-25-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 20, 2025 | MOption exercise Common Stock10b5-1 | +3,000 | $284.97 | $855k | 6,600 | Aug 20, 2025 |
| Aug 20, 2025 | SOpen-market sale Common Stock10b5-1 | -487 | $1,399.60 | $682k | 6,113 | Aug 20, 2025 |
| Aug 20, 2025 | SOpen-market sale Common Stock10b5-1 | -287 | $1,401.01 | $402k | 5,826 | Aug 20, 2025 |
| Aug 20, 2025 | SOpen-market sale Common Stock10b5-1 | -342 | $1,403.59 | $480k | 5,484 | Aug 20, 2025 |
| Aug 20, 2025 | SOpen-market sale Common Stock10b5-1 | -343 | $1,404.50 | $482k | 5,141 | Aug 20, 2025 |
| Aug 20, 2025 | SOpen-market sale Common Stock10b5-1 | -158 | $1,405.68 | $222k | 4,983 | Aug 20, 2025 |
| Aug 20, 2025 | SOpen-market sale Common Stock10b5-1 | -152 | $1,406.58 | $214k | 4,831 | Aug 20, 2025 |
| Aug 20, 2025 | SOpen-market sale Common Stock10b5-1 | -22 | $1,407.09 | $31k | 4,809 | Aug 20, 2025 |
| Aug 20, 2025 | SOpen-market sale Common Stock10b5-1 | -200 | $1,408.62 | $282k | 4,609 | Aug 20, 2025 |
| Aug 20, 2025 | SOpen-market sale Common Stock10b5-1 | -238 | $1,410.29 | $336k | 4,371 | Aug 20, 2025 |
| Aug 20, 2025 | SOpen-market sale Common Stock10b5-1 | -571 | $1,411.41 | $806k | 3,800 | Aug 20, 2025 |
| Aug 20, 2025 | SOpen-market sale Common Stock10b5-1 | -200 | $1,413.00 | $283k | 3,600 | Aug 20, 2025 |
| Aug 20, 2025 | MOption exercise Stock Optionderivative10b5-1 | -3,000 | $0.00 | $0 | 53,000 | Aug 20, 2025 |
Related signals
Other insiders at TransDigm Group INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | TransDigm Group INC | Joel Reiss Co-Chief Operating Officer | $4.3M 3,900 shares | -52% | |
| 23Weak | TransDigm Group INC | W Nicholas Howley director | $13M 10,132 shares | -32% | |
| 38Weak | TransDigm Group INC | Joel Reiss Co-Chief Operating Officer | $4.8M 3,900 shares | -52% | |
| 23Weak | TransDigm Group INC | W Nicholas Howley director | $12M 10,132 shares | -32% | |
| 28Weak | TransDigm Group INC | Joel Reiss Co-Chief Operating Officer | $4.2M 3,486 shares | -46% | |
| 31Weak | TransDigm Group INC | Joel Reiss Co-Chief Operating Officer | $510k 414 shares | -10% | |
| 43Moderate | TransDigm Group INC | W Nicholas Howley director | $13M 10,132 shares | -32% | |
| 43Moderate | TransDigm Group INC | W Nicholas Howley director | $13M 10,132 shares | -32% | |
| 43Moderate | TransDigm Group INC | W Nicholas Howley director | $13M 10,132 shares | -32% | |
| 58Moderate | TransDigm Group INC | Joel Reiss Co-Chief Operating Officer | $5.0M 3,900 shares | -52% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.